Results 61 to 70 of about 1,124 (174)

Amyloid Neuropathy: From Pathophysiology to Treatment in Light‐Chain Amyloidosis and Hereditary Transthyretin Amyloidosis

Annals of Neurology, Volume 96, Issue 3, Page 423-440, September 2024.
Amyloid neuropathy is caused by deposition of insoluble β‐pleated amyloid sheets in the peripheral nervous system. It is most common in: (1) light‐chain amyloidosis, a clonal non‐proliferative plasma cell disorder in which fragments of immunoglobulin, light or heavy chain, deposit in tissues, and (2) hereditary transthyretin (ATTRv) amyloidosis, a ...
Pitcha Chompoopong, Michelle L. Mauermann, Hasan Siddiqi, Amanda Peltier   +3 more
wiley   +1 more source

Droxidopa alters dopamine neuron and prefrontal cortex activity and improves attention-deficit/hyperactivity disorder-like behaviors in rats

, 2021
Finding alternative treatments for attention-deficit/hyperactivity disorder (ADHD) is crucial given the safety and efficacy problems of current ADHD medications. Droxidopa, also known as L-threo-dihydroxyphenylserine (L-DOPS), is a norepinephrine prodrug
Shen, Guofang, Shi, Wei-Xing, Dela Peña, Ike   +2 more
core   +1 more source

Determination of Carbidopa, Levodopa, and Droxidopa by high-performance liquid chromatography–tandem mass spectrometry

, 2018
Modern treatments o Parkinson’s disease include the use of carbidopa and droxidopa along with levodopa that demonstrates the necessity for their binary and simultaneous determination in pharmaceutical tablets and biological matrices.
Yengin Ç., Ertaş H., Ertaş F.N., Özdokur K.V., Engin E.   +4 more
core   +2 more sources

Istradefylline/L‐DOPA Parkinson's disease therapy and energy coupling

Neurology and Clinical Neuroscience, Volume 12, Issue 5, Page 296-305, September 2024.
Abstract Background Both dopamine and adenosine are physiologically involved in cellular energy metabolism. Aim Novel approaches targeting delaying progression strategies for Parkinson's disease (PD) examined the effects of long‐term use of A2AR antagonist/istradefylline (IST) adjunct to L‐DOPA (LD), nutshell IST‐LD, with an expected energy coupling ...
Naomi Kanzato, Koh Nakachi, Satsuki Mochizuki   +2 more
wiley   +1 more source

Associations of vitamin D receptor activators and calcimimetics with falls and effect modifications by physical activity: A prospective cohort study on the Japan Dialysis Outcomes and Practice Patterns Study

Therapeutic Apheresis and Dialysis, Volume 28, Issue 4, Page 547-556, August 2024.
Abstract Introduction This study aimed to examine the associations of vitamin D receptor activators (VDRA) and calcimimetics use with falls. Methods This is a prospective cohort study on hemodialysis patients in the Japan Dialysis Outcomes and Practice Patterns Study. We excluded those who were unable to walk.
Miho Murashima, Ryohei Yamamoto, Eiichiro Kanda, Noriaki Kurita, Hisashi Noma, Takayuki Hamano, Masafumi Fukagawa   +6 more
wiley   +1 more source

Simultaneous determination of droxidopa and carbidopa by carbon paste electrode functionalized with NiFe2O4 nanoparticle and 2-(4-ferrocenyl-1,2,3triazol-1-yl)-1-(naphthalen-2-yl) ethanone

, 2020
Droxidopa is a prescribed medication for the treatment of orthostatic hypertension in patients with pure autonomic failure and multiple system atrophy, which causes symptoms of lightheadedness and Parkinson's disease.
Hosseinzadeh, R., Kaykhaii, M., Mohammadi, S.Z., Beitollahi, H., Mohammadizadeh, N., Tajik, S.   +5 more
core  

New and combined treatments for cirrhosis and portal hypertension: effects on hemodynamics and hepatic fibrosis in experimental animal models [PDF]

, 2016
La cirrosi, la causa més freqüent d'hipertensió portal (HTP) en els països occidentals, és considerada una malaltia amb múltiples fases, que evoluciona des d'etapes inicials asimptomàtiques a un estat de cirrosi descompensada amb diverses manifestacions ...
Universitat Autònoma de Barcelona. Departament de Medicina, Rodríguez Navarro, Sarai   +1 more
core   +3 more sources

Sofosbuvir [PDF]

, 2014
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees.
Cong, Jasen, Baker, Danial E, Cada, Dennis J   +2 more
core   +1 more source

Prescription trends in Japanese advanced Parkinson's disease patients with non-motor symptoms: J-FIRST.

PLoS ONE
BackgroundNon-motor symptoms (NMS) are important factors when selecting treatments for patients with advanced Parkinson's disease (PD). We sought to elucidate the prescribing practices for advanced PD patients with NMS in Japanese clinical practice ...
Masahiro Nomoto, Yoshio Tsuboi, Kenichi Kashihara, Shih-Wei Chiu, Tetsuya Maeda, Hidemoto Saiki, Hirohisa Watanabe, Yasushi Shimo, Nobutaka Hattori, Takuhiro Yamaguchi, J-FIRST Investigators   +10 more
doaj   +1 more source

POS-800 DROXIDOPA FOR MANAGEMENT OF CHRONIC HYPOTENSION IN HAEMODIALYSIS

Kidney International Reports, 2021
A. Jayanti, M. ELEWA, P. Pimblett, D. Morris, H. Chande   +4 more
doaj   +1 more source